Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Hepion Pharmaceuticals, Inc. Common Stock (HEPA)

Pharmaceutical Preparations

https://www.hepionpharma.com

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

399 THORNALL STREET, FIRST FLOOR
EDISON, NJ

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/07/2014

Market Cap

4,117,382

Shares Outstanding

4,340,000

Weighted SO

4,337,682

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

ENVB --.--%

CWBR --.--%

ELEV --.--%

OCEA --.--%

AVRO --.--%

ZURA --.--%

EFTR --.--%

Beta

1.8570

Last Div

0.0000

Range

0.553-7.85

Chg

0.0353

Avg Vol

158743

Mkt Cap

4117382

Exch

NASDAQ

Country

US

Phone

732 902 4000

DCF Diff

-2.4210

DCF

3.6710

Div Yield

0.0000

P/S

37.5228

EV Multiple

-0.0685

P/FV

1.1560

Div Yield %

0.0000

P/E

-0.1452

PEG

0.0129

Payout

0.0000

Current Ratio

5.6193

Quick Ratio

5.6193

Cash Ratio

2.1679

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

2649.2297

CCC

-2649.2297

Gross Margin

0.4393

Op Margin

-316.7714

Pretax Margin

-289.2907

Net Margin

-258.5035

Eff Tax Rate

0.1108

ROA

-4.7196

ROE

-3.2866

ROCE

-6.9042

NI/EBT

0.8936

EBT/EBIT

0.9132

EBIT/Rev

-316.7714

Debt Ratio

0.0256

D/E

0.0433

LT Debt/Cap

0.0000

Total Debt/Cap

0.0415

Int Coverage

-874.5145

CF/Debt

-225.7350

Equity Multi

1.6874

Rec Turnover

0.0000

Pay Turnover

0.1378

Inv Turnover

0.0000

FA Turnover

0.7280

Asset Turnover

0.0183

OCF/Share

-5.9981

FCF/Share

-5.9977

Cash/Share

0.3647

OCF/Sales

-316.9918

FCF/OCF

0.9999

CF Coverage

-225.7350

ST Coverage

-225.7350

CapEx Coverage

-15570.0595

Div&CapEx Cov

-10755.5699

P/BV

1.1560

P/B

1.1560

P/S

37.5228

P/E

-0.1452

P/FCF

-0.1184

P/OCF

-0.1184

P/CF

-0.1184

PEG

0.0129

P/S

37.5228

EV Multiple

-0.0685

P/FV

1.1560

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 03, 17:15 Hepion Pharmaceuticals to Present at NASH-TAG 2024 GlobeNewswire Inc. Nov 28, 16:15 Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit GlobeNewswire Inc. Nov 10, 08:50 Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat GlobeNewswire Inc. Oct 25, 08:30 Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model

Revenue Product Segmentation